Radiogenomics Consortium (RGC)


The Radiogenomics Consortium was established in November 2009. The scientific hypothesis underlying the development of the consortium is that a cancer patient's likelihood of developing toxicity to radiation therapy is influenced by common genetic variations, such as single nucleotide polymorphisms (SNPs).

The Consortium members undertake collaborative projects to identify SNPs associated with adverse effects following radiotherapy, share data and samples, perform meta-analyses, and work together to submit research grant applications.

Return to Top


The objectives of the Radiogenomics Consortium are to expand knowledge of the genetic basis for differences in radiosensitivity and to develop assays to help predict the susceptibility of cancer patients for the development of adverse effects resulting from radiotherapy, through:

  • Fostering international collaborative research projects in radiogenomics through sharing of biospecimens and data;
  • Developing guidelines to improve the standardization of radiogenomics research;
  • Providing a framework for the efficient conduct and publication of original data meta-analyses of relevant studies;
  • Providing a forum and framework for discussion, development and pursuit of new research directions; and
  • Supporting the development of early career researchers.

Return to Top

Organizational Structure

A Coordinating Committee was established to run the Consortium. The lead coordinators for the Radiogenomics Consortium are Barry Rosenstein, Ph.D., of Icahn School of Medicine at Mount Sinai, New York, and Catharine West, Ph.D., of the University of Manchester, UK.

Other members of the Committee are:

  • Nicolaj Andreassen, M.D., Ph.D., of Aarhus University, Denmark
  • Gill Barnett, B.M., B.Ch., Ph.D., of University of Cambridge, UK
  • Soeren Bentzen, Ph.D., D.Sc., of University of Maryland, USA
  • Jenny Chang-Claude, Ph.D., of German Cancer Research Center (DKFZ)
  • Joe Deasy, Ph.D., of Memorial Sloan-Kettering Cancer Center, New York
  • Alison Dunning, Ph.D., of University of Cambridge, UK
  • Sarah Kerns, Ph.D., M.P.H., University of Rochester Medical Center, New York

The Committee also includes a representative from the NCI, Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N.

Lynda Rath of Icahn School of Medicine at Mount Sinai and Rebecca Elliot of the University of Manchester provide administrative support.

Return to Top


As of May 2013, membership of the Radiogenomics Consortium consists of about 150 individuals located at more than 80 institutions in 19 countries.

The Radiogenomics Consortium is open to all investigators interested in studying the relationship between genetic variation and radiation therapy toxicity.

Anyone interested in joining RGC should email Lynda Rath.

Return to Top

Funding Sources

Support for logistical needs of the Consortium has been provided by NCI's Epidemiology and Genomics Research Program (EGRP) in the Division of Cancer Control and Population Sciences (DCCPS) and the Radiation Research Program (RRP) in the Division of Cancer Treatment and Diagnosis (DCTD). Many members of the RGC are principal or co-investigators for grants that support research in radiogenomics and receive funding from National Cancer Institute, European Commission, Cancer Research UK, Canadian Institutes of Health, US Department of Defense, Deustsche Krebshilfe e.V, Health Research Fund, National Science Centre, and Spanish Ministry of Health.

Return to Top


Return to Top


Upcoming Meetings:

  • 8th Annual Radiogenomics Consortium Meeting
    MAASTRO Clinic, Maastricht, Netherlands, 2016

Past Meetings:

Return to Top


Lead Investigator(s)

NCI Contact

Return to Top